Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older
mRNA-1273 was authorized for children and adolescents aged 6 months through 17 years of age, administered as two doses given...
Staff
Jupiter Wellness Announces the Retirement of Approximately 10% of its Outstanding Shares
JUPITER, FL / ACCESSWIRE / June 17, 2022 / Jupiter Wellness, Inc. (NASDAQ:JUPW) today announced the purchase and retirement of...
BioCorRx Featured on LiveNOW from FOX
ANAHEIM, CA, June 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...
Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates
First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human...
Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference
Results to be Presented in Late-Breaking SessionSAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company...
ExCellThera announces submission of Drug Master File for UM171
MONTRÉAL, June 17, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions...
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
CY6463 alleviated mitochondrial dysfunction and reduced inflammation in preclinical models of mitochondrial complex 1 deficiency Data provide support for ongoing...
Codexis Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Bioconjugation of Native Peptides
Collaboration with Merck published in Science magazine REDWOOD CITY, Calif., June 17, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS),...
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
Top-line Efficacy Results Expected in Approximately 6 to 8 WeeksBRIDGEWATER, N.J., June 17, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc....
Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil
Recent Company Submission in Response to FDA Request Extends PDUFA DateSOUTH SAN FRANCISCO, Calif., June 17, 2022 (GLOBE NEWSWIRE) --...
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022
Presentation to be highlighted in the Best of International Liver CongressGAITHERSBURG, Md., June 17, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc....
Quotient Limited to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on June 22nd
JERSEY, Channel Islands, June 17, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that...
HEXO Acknowledges Zenabis Group CCAA Filing
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 2, 2022...
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back...
U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation
DENVER, June 17, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”),...
Stephen Bardin to Join atai Life Sciences as CFO Designate
Stephen Bardin will join as CFO Designate on June 27, 2022After a transition period, atai’s current CFO Greg Weaver will...
Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
BASEL, Switzerland and NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE)...
The Ensign Group, Inc. Declares Quarterly Dividend of $0.055 Per Share
SAN JUAN CAPISTRANO, Calif., June 17, 2022 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (NASDAQ: ENSG), the parent company of...
Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics studyAdalimumab’s high-concentration 100 mg/mL formulation aims...
Cresemba® sales in Asia Pacific region trigger sales milestone payment to Basilea from Pfizer
Basel/Allschwil, Switzerland, June 17, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that the sales of...